Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Vineetha Vasukuttan"'
Autor:
George Amato, Vineetha Vasukuttan, Danni Harris, Lucas Laudermilk, Jennifer Lucitti, Scott Runyon, Rangan Maitra
Publikováno v:
Molecules, Vol 27, Iss 17, p 5672 (2022)
Selective modulation of peripheral cannabinoid receptors (CBRs) has potential therapeutic applications in medical conditions, including obesity, diabetes, liver diseases, GI disorders and pain. While there have been considerable efforts to produce se
Externí odkaz:
https://doaj.org/article/c6b92781d8634a3b8718e9bbf0b5f6e7
Autor:
Elaine A. Gay, Dongliang Guan, Kalynn Van Voorhies, Vineetha Vasukuttan, Kelly M. Mathews, Joyce Besheer, Chunyang Jin
Publikováno v:
J Med Chem
The neuropeptide relaxin-3/RXFP3 system is involved in many important physiological processes such as stress responses, appetite control, and motivation for reward. To date, pharmacological studies of RXFP3 have been limited to peptide ligands. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34bc46e1e337845db6f9a86d0b113122
https://europepmc.org/articles/PMC9255433/
https://europepmc.org/articles/PMC9255433/
Autor:
Shaobin Wang, Scott P. Runyon, Lucas Laudermilk, Vineetha Vasukuttan, Ravi Kumar Vyas Devambatla, Rangan Maitra, Sanju Narayanan, Rodney W. Snyder, Chunyang Jin, Donghua Dai
Publikováno v:
Journal of Medicinal Chemistry. 64:3006-3025
Apelin receptor agonism improves symptoms of metabolic syndrome. However, endogenous apelin peptides have short half-lives, making their utility as potential drugs limited. Previously, we had identified a novel pyrazole-based agonist scaffold. System
Autor:
Sanju Narayanan, Donghua Dai, Ravi Kumar Vyas Devambatla, Vincent Albert, Nicolas Bruneau-Latour, Vineetha Vasukuttan, Stephane Ciblat, Kenneth Rehder, Scott P. Runyon, Rangan Maitra
Publikováno v:
Bioorganicmedicinal chemistry. 66
The apelin receptor (APJ) is a target for cardiovascular indications. Previously, we had identified a novel pyrazole-based agonist 1 ((S)-N-(1-(cyclobutylamino)-1-oxo-5-(piperidin-1-yl)pentan-3-yl)-1-cyclopentyl-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-
Autor:
Dongliang Guan, Md Toufiqur Rahman, Elaine A. Gay, Vineetha Vasukuttan, Kelly M. Mathews, Ann M. Decker, Alexander H. Williams, Chang-Guo Zhan, Chunyang Jin
Publikováno v:
J Med Chem
The central relaxin-3/RXFP3 system plays important roles in stress responses, feeding, and motivation for reward. However, exploration of its therapeutic applications has been hampered by the lack of small molecule ligands and the cross-activation of
Autor:
Rangan Maitra, Timothy W. Lefever, Yanan Zhang, George S. Amato, Amruta Manke, Vineetha Vasukuttan, Scott P. Runyon, Danni L. Harris, Ricardo A. Cortes, Rodney W. Snyder, Shaobin Wang, Robert W. Wiethe
Publikováno v:
J Med Chem
Type 1 cannabinoid receptor (CB1) antagonists have demonstrated promise for the treatment of obesity, liver disease, metabolic syndrome, and dyslipidemias. However, the inhibition of CB1 receptors in the central nervous system can produce adverse eff
Autor:
Rodney W. Snyder, George S. Amato, Y Yueh, Robert W. Wiethe, Rangan Maitra, Ann M. Decker, Scott P. Runyon, Amruta Manke, Vineetha Vasukuttan
Publikováno v:
J Med Chem
Peripherally restricted CB1 receptor antagonists may be useful in treating metabolic syndrome, diabetes, liver diseases, and gastrointestinal disorders. Clinical development of the centrally acting CB1 inverse agonist otenabant (1) was halted due to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be946dcb30df8043c6eb2a16c36cf355
https://europepmc.org/articles/PMC7656562/
https://europepmc.org/articles/PMC7656562/
Autor:
Scott P. Runyon, Rangan Maitra, Rodney W. Snyder, George S. Amato, Robert W. Wiethe, Amruta Manke, Vineetha Vasukuttan
Publikováno v:
Bioorg Med Chem
Antagonists of type 1 cannabinoid receptors (CB1) may be useful in treating diabetes, hepatic disorders, and fibrosis. Otenabant (1) is a potent and selective CB1 inverse agonist that was under investigation as an anti-obesity agent, but its developm
Publikováno v:
The FASEB Journal. 33